Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program

Dow Jones

2024-12-20

By Stephen Nakrosis

Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors.

The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors.

Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types.

The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added.

Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 19, 2024 17:06 ET (22:06 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492848050"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492848050\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492848050?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 06:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492848050","market":"sg","top_or_hot":-1,"title":"Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors. \n</p>\n<p>\n  The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors. \n</p>\n<p>\n  Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types. \n</p>\n<p>\n  The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added. \n</p>\n<p>\n  Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 17:06 ET (22:06 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-20 06:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors. \n</p>\n<p>\n  The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors. \n</p>\n<p>\n  Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types. \n</p>\n<p>\n  The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added. \n</p>\n<p>\n  Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 17:06 ET (22:06 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492848050","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492848050","pubTimestamp":1734645960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors.The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors.Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types.The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added.Pyxis said its current cash position is expected to fund its planned trials o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PYXS":"Pyxis Oncology, Inc."},"translate_title":"Pyxis Oncology将专注于PYX-201，暂停PYX-106项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors. \n\n\n  The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors. \n\n\n  Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types. \n\n\n  The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added. \n\n\n  Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 17:06 ET (22:06 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}